ARCUS BIOSCIENCES INC (RCUS) — insider trading
Health Care · NYSE
ARCUS BIOSCIENCES INC (RCUS) has 29 reported SEC Form 4 insider transactions in our data, including 10 open-market sales among the most recent 29 (latest 2026-08-21).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-21 | Azoy Alexander | Officer (Chief Accounting Officer) | Option exercise / conversion (derivative) | 2,827 | — | $0 | Form 4 |
| 2026-08-21 | Azoy Alexander | Officer (Chief Accounting Officer) | Open-market sale | 2,827 | $30.00 | $84.8K | Form 4 |
| 2026-08-21 | Azoy Alexander | Officer (Chief Accounting Officer) | Option exercise / conversion | 2,827 | $15.44 | $43.6K | Form 4 |
| 2026-07-10 | Jaen Juan C. | Officer (President) | Open-market sale | 268 | $29.40 | $7.9K | Form 4 |
| 2026-07-10 | Jaen Juan C. | Officer (President) | Open-market sale | 19,799 | $28.61 | $566.4K | Form 4 |
| 2026-07-09 | Jaen Juan C. | Officer (President) | Open-market sale | 48,502 | $30.05 | $1.46M | Form 4 |
| 2026-06-24 | Jaen Juan C. | Officer (President) | Open-market sale | 6,431 | $29.66 | $190.7K | Form 4 |
| 2026-06-23 | Jaen Juan C. | Officer (President) | Open-market sale | 1,697 | $28.06 | $47.6K | Form 4 |
| 2026-06-23 | Jaen Juan C. | Officer (President) | Open-market sale | 14,067 | $27.69 | $389.5K | Form 4 |
| 2026-06-22 | Jaen Juan C. | Officer (President) | Open-market sale | 9,236 | $27.03 | $249.7K | Form 4 |
| 2026-06-11 | PERLMAN ANDREW J | Director | Grant / award / vesting (derivative) | 16,900 | — | $0 | Form 4 |
| 2026-06-11 | PERLMAN ANDREW J | Director | Grant / award / vesting | 5,700 | — | $0 | Form 4 |
| 2026-06-11 | Ribas Antoni | Director | Grant / award / vesting (derivative) | 16,900 | — | $0 | Form 4 |
| 2026-06-11 | Ribas Antoni | Director | Grant / award / vesting | 5,700 | — | $0 | Form 4 |
| 2026-06-11 | FALBERG KATHRYN E | Director | Grant / award / vesting (derivative) | 16,900 | — | $0 | Form 4 |
| 2026-06-11 | FALBERG KATHRYN E | Director | Grant / award / vesting | 5,700 | — | $0 | Form 4 |
| 2026-06-11 | Lacey David L. | Director | Grant / award / vesting (derivative) | 16,900 | — | $0 | Form 4 |
| 2026-06-11 | Lacey David L. | Director | Grant / award / vesting | 5,700 | — | $0 | Form 4 |
| 2026-06-11 | Tang Carolyn C. | Officer (General Counsel) | Option exercise / conversion (derivative) | 34,090 | $2.57 | $87.7K | Form 4 |
| 2026-06-11 | Tang Carolyn C. | Officer (General Counsel) | Option exercise / conversion | 34,090 | $2.57 | $87.7K | Form 4 |
| 2026-06-11 | KANEKO YASUNORI | Director | Grant / award / vesting (derivative) | 16,900 | — | $0 | Form 4 |
| 2026-06-11 | KANEKO YASUNORI | Director | Grant / award / vesting | 5,700 | — | $0 | Form 4 |
| 2026-06-11 | Machado Patrick | Director | Grant / award / vesting (derivative) | 16,900 | — | $0 | Form 4 |
| 2026-06-11 | Machado Patrick | Director | Grant / award / vesting | 5,700 | — | $0 | Form 4 |
| 2026-06-11 | Lambert Nicole | Director | Grant / award / vesting (derivative) | 16,900 | — | $0 | Form 4 |
| 2026-06-11 | Lambert Nicole | Director | Grant / award / vesting | 5,700 | — | $0 | Form 4 |
| 2026-06-01 | Azoy Alexander | Officer (Chief Accounting Officer) | Open-market sale | 2,562 | $25.77 | $66.0K | Form 4 |
| 2026-05-11 | Goeltz II Robert C. | Officer (Chief Financial Officer) | Open-market sale | 7,763 | $25.63 | $199.0K | Form 4 |
| 2025-12-16 | Ribas Antoni | Director | Bona fide gift | 5,050 | — | $0 | Form 4 |
Ask the chat about RCUS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARCUS BIOSCIENCES INC (RCUS).
Last updated 2026-08-21 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.